Gene News and Research

Latest Gene News and Research

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma.

11 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Gene variant that increases risk of type 2 diabetes identified in Latino individuals

A genetic analysis of DNA samples of approximately 3,700 Mexican and U.S. Latino individuals identified a gene variant that was associated with a 5-fold increase in the prevalence of type 2 diabetes, findings that may have implications for screening in this population, according to a study in the June 11 issue of JAMA, a diabetes theme issue.

11 Jun 2014

Human herpes simplex virus infected human approximately 1.6 million years ago

Researchers at the University of California, San Diego School of Medicine have identified the evolutionary origins of human herpes simplex virus (HSV) -1 and -2, reporting that the former infected hominids before their evolutionary split from chimpanzees 6 million years ago while the latter jumped from ancient chimpanzees to ancestors of modern humans - Homo erectus - approximately 1.6 million years ago.

11 Jun 2014

Study presents oxytocin as latest treatment target for age-related muscle wasting

Researchers at the University of California, Berkeley, have discovered that oxytocin -- a hormone associated with maternal nurturing, social attachments, childbirth and sex -- is indispensable for healthy muscle maintenance and repair, and that in mice, it declines with age.

11 Jun 2014

Scientists find out what goes wrong in cancer cell

Cancer - about one in three Europeans is confronted with this diagnosis during their lifetime. Scientists at the German Cancer Research Center DKFZ in Heidelberg are investigating the development of cancerous cells to find out how their growth is controlled and what goes wrong in a cancer cell.

11 Jun 2014

Researchers discover new class of tumor

This is the story of two perfectly harmless genes. By themselves, PAX3 and MAML3 don't cause any problems. However, when they combine during an abnormal but recurring chromosomal mismatch, they can be dangerous.

11 Jun 2014

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

11 Jun 2014

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

In the largest study of its kind published to date, an international team of researchers in Mexico and the United States has discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is rare elsewhere.

11 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Wistar findings suggest means of boosting initial immune response

Your first response to an infectious agent or antigen ordinarily takes about a week, and is relatively weak. However, if your immune system encounters that antigen a second time, the so-called memory response is rapid, powerful, and very effective.

10 Jun 2014

Researchers solve structure of key protein that drives DNA copying in plasmids

Staph infections that become resistant to multiple antibiotics don't happen because the bacteria themselves adapt to the drugs, but because of a kind of genetic parasite they carry called a plasmid that helps its host survive the antibiotics.

10 Jun 2014

African-American women at increased risk for deadlier breast cancers, study finds

A research study led by cancer specialists at MedStar Washington Hospital Center found that African-American women frequently present with biologically less favorable subtypes of breast cancer.

10 Jun 2014

BP history affects late-life brain pathology

The relationship between late-life blood pressure and damage to the brain is modified by midlife hypertension history, research shows.

9 Jun 2014

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.

9 Jun 2014

New findings on cellular signaling offer potential implications ranging from agriculture to cancer research

A team of researchers studying a flowering plant has zeroed in on the way cells manage external signals about prevailing conditions, a capability that is essential for cells to survive in a fluctuating environment.

9 Jun 2014

University of Indianapolis breaks ground June 19 on $28 million Health Pavilion

The University of Indianapolis will break ground June 19 on a four-story, $28 million Health Pavilion that will house UIndy's healthcare- and wellness-related academic programs as well as industry partners and clinical facilities to serve the community.

9 Jun 2014

Rubicon signs agreements with 7 distributors to expand availability of DNA library preparation products

Rubicon Genomics, Inc., today announced that it signed agreements with seven distributors in Europe to expand the availability of its leading DNA library preparation products, including ThruPLEX®-FD Prep Kit and PicoPLEX™ DNA-seq Kit for use with Illumina® next-generation sequencing (NGS) systems and PicoPLEX™ WGA Kit for use on arrays, and to prepare for new product launches planned for the coming months.

9 Jun 2014

Research finding paves way for targeted approaches to treating cancer patients

Twelve years ago, UNC School of Medicine researcher Brian Strahl, PhD, found that a protein called Set2 plays a role in how yeast genes are expressed - specifically how DNA gets transcribed into messenger RNA. Now his lab has found that Set2 is also a major player in DNA repair, a complicated and crucial process that can lead to the development of cancer cells if the repair goes wrong.

9 Jun 2014

Gene News and Research

Latest Gene News and Research

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Gene variant that increases risk of type 2 diabetes identified in Latino individuals

Human herpes simplex virus infected human approximately 1.6 million years ago

Study presents oxytocin as latest treatment target for age-related muscle wasting

Scientists find out what goes wrong in cancer cell

Researchers discover new class of tumor

EU-funded project aims to identify potential new targets for cancer therapy

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Wistar findings suggest means of boosting initial immune response

Researchers solve structure of key protein that drives DNA copying in plasmids

African-American women at increased risk for deadlier breast cancers, study finds

BP history affects late-life brain pathology

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

New findings on cellular signaling offer potential implications ranging from agriculture to cancer research

University of Indianapolis breaks ground June 19 on $28 million Health Pavilion

Rubicon signs agreements with 7 distributors to expand availability of DNA library preparation products

Research finding paves way for targeted approaches to treating cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care